Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SSK1 is a compound that selectively kills senescent cells and is a precursor for β-galactosidase, which can reduce the inflammatory response of the body. SSK1 can activate the phosphorylation of p38 MAPK and MKK3/MKK6 in senescent cells, and promote mitochondrial DNA damage in senescent cells.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 215.00 | |
5 mg | In stock | $ 537.00 | |
10 mg | In stock | $ 775.00 | |
25 mg | In stock | $ 1,190.00 | |
50 mg | In stock | $ 1,590.00 |
Description | SSK1 is a compound that selectively kills senescent cells and is a precursor for β-galactosidase, which can reduce the inflammatory response of the body. SSK1 can activate the phosphorylation of p38 MAPK and MKK3/MKK6 in senescent cells, and promote mitochondrial DNA damage in senescent cells. |
In vitro | SSK1 (0.5 μM; 12-72 h) is activated by lysosomal β-galactosidase, selectively kills senescent cells by activating p38 MAPK, and inducing apoptosis[1]. |
In vivo | Lung-injured mice (3-6 months old) received intratracheal administration of bleomycin (1.5 mg/kg) and were subjected to intraperitoneal injection of SSK1 (0.5 mg/kg) or vehicle (DMSO) for two consecutive days each week for 4 weeks. The results indicate that SSK1 can eliminate SA-β-gal-positive senescent cells and reduce aging-related markers in vivo[1]. |
Molecular Weight | 788.61 |
Formula | C31H34F2N4O18 |
CAS No. | 2629250-69-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 150 mg/mL (190.20 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SSK1 2629250-69-5 MAPK p38 MAPK SSK-1 SSK 1 inhibitor inhibit